跳转至内容
Merck
所有图片(1)

Key Documents

59590-U

Supelco

Discovery® C8 (5 µm) HPLC Columns

L × I.D. 2 cm × 4 mm Supelguard Guard Cartridge, pkg of 2 ea, Guard Cartridge holder required for use

登录查看公司和协议定价


About This Item

分類程式碼代碼:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Discovery® C8 Supelguard 保护柱芯, 5 μm particle size, L × I.D. 2 cm × 4 mm

材料

stainless steel column

品質等級

agency

suitable for USP L7

產品線

Discovery®

特點

endcapped

包裝

pkg of 2 ea

技術

HPLC: suitable
LC/MS: suitable

長度 × 內徑

2 cm × 4 mm

表面積

200 m2/g

基質

fully porous particle

基質活性組

C8 (octyl) phase

粒徑

5 μm

孔徑

180 Å

工作pH值

2-8

應用

food and beverages

分離技術

reversed phase

正在寻找类似产品? 访问 产品对比指南

包裝

适用于 4.0mm 内径和 4.6mm 内径的分析柱

推薦產品

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

法律資訊

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

G L Bundy et al.
The Journal of biological chemistry, 261(2), 747-751 (1986-01-15)
The gorgonian coral Pseudoplexaura porosa contains a lipoxygenase capable of converting exogenous arachidonic acid into (8R)-8-hydroperoxy-5,9,11,14-eicosatetraenoic acid. The (8R)- (or 8-L-) configuration in this product, opposite to that observed in previously reported 8-lipoxygenase products, was determined unambiguously by comparison of
M Q Zhang et al.
Die Pharmazie, 46(10), 687-700 (1991-10-01)
The rapid growth in the quinolone research changed the whole face of the previous SAR concepts. So far structural modifications at all positions of the quinolone nucleus except the 4-oxo group have successfully lead to the discovery of potent antimicrobial
Simeon Grazio et al.
Clinical and experimental rheumatology, 31(5), 665-671 (2013-06-07)
Using proteomic approach in this study, we sought to identify proteins with heparin affinity associated with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and non-inflammatory arthritis (NIA). Plasma samples from adult RA, PsA and NIA patients, 20 of each, were collected.
Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of
Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门